Company will temporarily pause CONNECT2 and focus efforts on ongoing CONNECT1-EDO51 study of PGN-EDO51 in DMD, with 10 mg/kg results expected in the third quarter of 2025 No new safety issues have ...

“Today, we reported initial results from FREEDOM-DM1, which showed robust splicing correction in patients with DM1 following a single dose of PGN-EDODM1. We believe these data contribute to the ...

BOSTON, February 24, 2025--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of ...

These results were measured by a 22-gene panel 28 days after dosing. A dose-dependent increase in muscle tissue concentrations of PGN-EDODM1 was also noted on day 28. Although single-dose studies ...

today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results ...

The CONNECT2-EDO51 trial, which is designed to test PepGen’s PGN-EDO51 exon-skipping therapy ... we decided to pause CONNECT2 until we are able to review results from the 10 mg/kg cohort in ...